TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of ROTEM-based Coagulation Surveillance on Reducing Blood Product Utilization During Complex Spine Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \> 18 and \< 80 years old.~2. Elective spine surgery cases, with a traditional open posterior approach and involving fusion of at least 5 levels.~3. Normal coagulation profile (PT/INR, aPTT) and normal platelets count on pre-operative evaluation.~4. Preoperative hemoglobin Level \>10 g/dl.~5. OR time \> 4 hours.~6. No contraindication for the use of anti-fibrinolytic therapy (Tranexamic acid).~Exclusion Criteria:~1. Age \< 18 or age \> 80 years old.~2. Anterior spine surgeries or posterior spine surgeries involving \<5 levels.~3. Minimally invasive spine surgeries.~4. Patients with known coagulopathies or bleeding tendencies or patients with abnormal coagulation laboratory values at baseline.~5. Patients with Hemoglobin level of \<10 g/dl on preoperative baseline laboratory values.~6. Trauma and Emergency spine surgeries.~7. Patients with spine malignancy diagnosis, either primary or metastatic.~8. OR time \< 4 hours.~9. Patients who refuse to use allogenic blood products.~10. Patients with contraindications for the use of anti-fibrinolytic therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- ROTEM Group (Type: EXPERIMENTAL): Patients who are randomized to receive ROTEM
- Control Group (Type: OTHER): Patients who are randomized not to receive ROTEM

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Nutritional Strategies for Metabolic Health in Aging

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 60-80 years of age~* Body mass index of 30-40 kg/m2~* Participants must be capable of understanding the consent process~* Participants must be capable of signing the consent form~* Participants must have access to transportation to the clinic site~Exclusion Criteria:~* Creatinine \>1.6~* Serum glutamate pyruvate transaminase \>2 times normal~* Resting blood pressure above 160/90 mmHg~* Use of Gemfibrozil~* Use of corticosteroids~* Previously diagnosed diabetes (fasting blood glucose ≥ 126 mg/dl)~* History of kidney or liver disease~* Heart disease as indicated by interventional procedures~* Recent history of alcoholism~* Physical or neurological disorder that would prevent them from completing the functional tests~* Lactose intolerance~* Active cancer within the last two years~* Chronic inflammatory conditions that preclude completion of functional tests

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Experimental Meal Replacement (Type: EXPERIMENTAL): Participants randomized to this arm will consume 5 servings/day of experimental meal replacement in conjunction of 400 kcal of solid food for 12 weeks during the weight loss portion of the trial. This will be followed by the consumption of 1 serving/day of experimental meal replacement for 12 weeks during the weight maintenance portion of the trial.
- Bariatrics Advantage Meal Replacement (Type: ACTIVE_COMPARATOR): Participants randomized to this arm will consume 5 servings/day of Bariatrics Advantage meal replacement in conjunction of 400 kcal of solid food for 12 weeks during the weight loss portion of the trial. This will be followed by the consumption of 1 serving/day of Bariatrics Advantage meal replacement for 12 weeks during the weight maintenance portion of the trial.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Vetal Laban Intervention Trial Assessing Bowel Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females aged 18 to 65 years~* Subjects fulfilling Rome III criteria for IBS~* Sufficient health and orientation for participating in the trial~* Obtained his/her informed consent after verbal and written information.~* Have a high probability for compliance with and completion of the study.~* Body Mass Index (BMI) between 19 and 35.~Exclusion Criteria:~* Diagnosed or suspected organic gastrointestinal disease (i.e. colitis, Crohn's disease, celiac disease, major bowel surgery, recurrent diverticulitis) or severely impaired general health including cancer and cancer therapy.~* Lactose intolerance~* Unwillingness to refrain from probiotic use during the trial~* Use of antibiotics within the 3 preceding months prior to recruitment~* Pregnant, planning pregnancy or lactating~* Expected major lifestyle changes related to nutrition, exercise, travelling etc.~* Participation in a clinical trial with an investigational product or drug within 3 months prior to screening.~* Substance abuse~* Subjects unable to read and understand the questionnaires

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Vetal Laban active (Type: ACTIVE_COMPARATOR): Vetal Laban with L. acidophilus
- Placebo (Type: PLACEBO_COMPARATOR): Vetal Laban -like product without L. acidophilus

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: LXRs, Cholesterol Metabolism and Uterine Dystocia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing C-section for a dystocia: 2 to 3 hours of stagnation in labor progress are observed (ie no increasing dilation, and uterine contractions less that 3-5 per 10 minutes) in spite of measures taken to overcome dystocia (oxytocin injection and artificial breaking of waters)~* the child is alive~* the child does not have apriori known malformations that could interfere with a vaginal birth~* foetus in cephalic position~* full term pregnancy (\>= 37 weeks of amenorrhea)~* single birth~* patient has signed consent~* patient is affiliated with a social security system~Exclusion Criteria:~* vaginal birth~* programmed C-section~* C-section is chosen because the fetus has a cardia rhythm problem, and there is no stagnation in the labor process~* multiple pregnancy~* the child is in a breech position~* premature birth (\<37 weeks amenorrhea)~* in utero fetal death~* fetal malformation known before birth that could interfere with a vaginal birth~* non french-speaking patient (impossible to correctly inform the patient)~* patient under guardianship

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: None): Control group: these patients have mechanical dystocia; cholesterol metabolism factors are a priori not involved.
- Group 2 (Type: None): These patients have uterine dystocia

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Suboptimal Weight Loss After Gastric Bypass Surgery

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Body mass index (BMI) \>40kg/m2, or BMI\>35kg/m2 with comorbidities~* healthy volunteers with suboptimal weight loss~* health with significant weight regain after Roux-n-Y Gastric Bypass, defined as failure to lose at least 40% Excess Weight Loss by 12 months postoperatively.~Significant weight regain: Regain of ≥15% of total weight lost after the first postoperative year.~Exclusion Criteria:~* Pregnancy~* enrollment in another obesity treatment~* previous revisional bariatric surgery~* planned bariatric surgery~* past or ongoing drug or alcohol abuse~* physical or mental impairment that interferes with the ability to comply to treatment~* history of severe psychological disorder~* history of severe eating disorder~* current medication known to affect appetite or induce weight loss

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Outpatient group (Type: EXPERIMENTAL): Multidisciplinary outpatient programme including both individual and group-based therapy. During the first visit, every patient will have an individual consultation with the dietician, physiotherapist and psychiatric nurse. After this, the patients will be followed up in groups every month for the first four months and every two months afterwards up to one year. The intervention will focus on nutritional education, healthy eating, increased physical activity levels (aiming initially at 10 minutes/day, then increasing to 30 minutes/day) and cognitive therapy.
- Inpatient group (Type: EXPERIMENTAL): Inpatient lifestyle programme offered at a rehabilitation center consisting of a continuous care weight loss program, with three intermittent stays (each with three-week duration) over a one year period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Stenting of Haemodialysis Acces Trial

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients of 18 years of age~* Patients have a life expectancy of at least 2 years~* Signed informed consent~* Recurrent stenosis at the venous anastomosis or in the draining vein of a loop arterio venous fistula, within 2 cm from the anastomosis.~Exclusion Criteria:~* Patient unsuitable for administration of contrast agent~* Pregnancy~* Dementia or altered mental status that would prohibit giving conscious informed consent~* Need for adjunctive major surgical or vascular procedures within one month

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): viabahn stent-graft

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Trial to Evaluate the Efficacy and Safety of YH12852 in Patients With Functional Dyspepsia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects must be willing and able to provide written informed consent.~2. BMI of \< 35 kg/m2~3. Patients experiencing one or more of functional dyspepsia symptoms beginning at least 6 months prior according to Rome III criteria, with the symptom(s) evident over the last 3 months at the time of screening~4. Patients with no evidence of organic lesions based on upper GI endoscopy, which could be the cause of dyspeptic symptoms~5. Women of childbearing potential (WOCBP) must have a negative pregnancy test result at the screening visit and use an adequate method of contraception to avoid pregnancy throughout the study~Exclusion Criteria:~1. Women who are pregnant or breastfeeding.~2. Women with a positive pregnancy test result on enrollment or prior to investigational product administration.~3. Subjects with a history of surgery that could affect gastrointestinal motility~4. Subjects with inflammatory bowel disease~5. Clinically significant chronic infection (eg. AIDS, etc), or significant medical or psychiatric illness.~6. Serious cardiovascular disease (including QT prolongation defined as QTc interval ≥ 450msec) or respiratory disease~7. History of alcohol or drug abuse within the previous one year.~8. Subjects with mental illness (e.g. schizophrenia, dementia etc) that may render the inability to complete the study~9. Physical and Laboratory Test Findings~10. Administration of any other investigational product or participation in other clinical trials within 3 months prior to randomization.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- YH12852 0.1 mg (Type: EXPERIMENTAL): twice daily for 4 weeks
- YH12852 0.25 mg (Type: EXPERIMENTAL): twice daily for 4 weeks
- YH12852 0.5 mg (Type: EXPERIMENTAL): twice daily for 4 weeks
- Placebo (Type: PLACEBO_COMPARATOR): twice daily for 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Use of Sorafenib and/or Regorafenib in Liver Cancer (Hepatocellular Carcinoma) Subsequent to Another Systemic First-line Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of hepatocellular cancer in stage BCLC-B or BCLC-C~* Decision to initiate treatment with Nexavar (sorafenib) and/or Stivarga (regorafenib) as 2nd-line or beyond treatment was made as per investigator's routine treatment practice. Stivarga (regorafenib) must be used according to its indication, i.e. after prior progression under Nexavar (sorafenib) treatment.~Exclusion Criteria:~* Patients concurrently participating in an investigational program for the treatment of HCC with interventions outside of routine clinical practice.~* Stivarga (regorafenib) treatment without prior therapy with Nexavar (sorafenib). NOTE: Nexavar (sorafenib) treatment could have been given as treatment for HCC outside of this non-interventional study. In this case Stivarga (regorafenib) would NOT constitute the second-line therapy after direct pretreatment with Nexavar (sorafenib) but e.g. 3rd-line treatment directly after a different drug.~* Contra-indications according to the local marketing authorization.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with HCC (Type: None): Treated with Nexavar and/or Stivarga as ≥ 2nd-line systemic treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of an Early Screening Test of Chronic Rejection and of Operational Tolerance by MicroArray in Renal Graft (Protocol DPRC Array)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 18 to 65 years old,~* Donor's age ≤ 60 years old,~* Patients receiving a first cadaveric renal graft,~* Patients taking immunosuppressant treatment including an induction with Simulect at day 0 and day 4, FK 506 (Prograf®) associated with Cellcept and steroids (for three months),~* Patients don't taking indispensable anticoagulant treatment.~Exclusion Criteria:~* Patient's age \< 18 or \> 65 years old,~* Donor's age ≥ 60 years old,~* Pregnant women or breast feeding women,~* Patients receiving a retransplantation, a kidney and pancreas graft or a graft from a living donor,~* Patients taking immunosuppressant treatment without FK 506 (Prograf®), Cellcept and steroids.~* Patients with coagulation troubles or taking indispensable anticoagulant treatment,~* No biopsy before graft.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: OTHER): Patients aged 18 to 65 years old receiving a first cadaveric renal graft.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Trial Comparing N of 1 Trials to Standard Practice to Improve Adherence to Statins in Patients With Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Established diagnosis of type 1 or 2 diabetes~* Age 18-80 years~* Indication for a statin by the 2003 Canadian Diabetes Association (CDA) Clinical Practice Guidelines~* Willingness to re-try a statin despite previous apparent intolerance~* Provision of signed informed consent~Exclusion Criteria:~* Contraindication to a statin: previous rhabdomyolysis, active liver disease or unexplained persistent elevations of serum transaminases (CK, AST, ALT \>three times upper limit of normal), pregnancy or lactation~* Impaired renal function: severe renal insufficiency (creatinine clearance \<30 ml/min)~* Presence of a condition such as malignancy for which the one-year prognosis is poor~* Inability of the patient to comply with the rigorous conditions of the trial~* Any other condition deemed to render the study harmful to the participant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): N of 1 trials of statin therapy
- 2 (Type: OTHER): usual care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell Transplantation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
* Patients of any age who have previously undergone allogeneic hematopoietic transplantation and have evidence of donor cell engraftment (\>20% donor cell within three months of study entry)~* Expected survival \>4 weeks~* CML patients with molecular, cytogenetic or hematologic relapse following allogeneic transplantation~  1. Molecular relapse- patients are eligible if bcr/abl is detectable at any time after day 180 post-allogeneic transplantation or if a negative bcr/abl PCR test was documented post-transplantation and the bcr/abl test is now positive by consecutive PCR determinations at least 4 weeks apart.~ 2. Cytogenetic relapse-patients are eligible if standard cytogenetics demonstrate \>10% t (9,22) positive cells greater than 60 days after myeloablative transplantation or 10% t (9,22) positive cells greater than 100 days after nonmyeloablative transplantation.~* CML patients with accelerated phase or blast crisis following allogeneic transplantation~* Patients with CLL, NHL, MM, or HD who have evidence of disease relapse or persistent disease at 60 days post-allo BMT and/or:~  1. MM- patients with a rising M-protein is detectable at 180 days post-transplant~ 2. NHL - patients with molecular evidence of disease (bcl-2, t (4,11), etc.) at 180 days post transplant~ 3. CLL, NHL or HD - patients with clear cut evidence of tumor growth at any time post-transplant are eligible~* Patients undergoing an HLA -identical or 5/6 antigen match transplant from a related or unrelated donor~* Patient's original donor must be available for lymphocyte donation~* There must be no evidence of active acute or graft-versus-host disease and patients should be off all immunosuppressive agents for, at least, two weeks prior to DLI. Patients on stable dose of methylprednisolone (\<16 mg/d) without evidence of active GVHD are also eligible.~* Patients must have a Zubrod PS\<2 (see appendix 7), Cr\<2.5, bilirubin \<3, and transaminases (SGPT, SGOT) \<4x normal~* Patient must be able to sign informed consent

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CD8 DLI (Type: EXPERIMENTAL): CD8 depleted DLI (Depleted Donor Lymphocyte Infusions)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Alfimeprase's Ability to Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age 18 or older~* Arteriographically confirmed acute PAO of the lower extremity with onset of symptoms within 14 days prior to randomization~* Acute index limb ischemia classified as SVS/ISCVS Class I or IIa caused by occlusion of a native artery and/or bypass graft (vein or prosthetic). Only Class I subjects with abrupt onset of ischemic rest pain or abrupt onset/progression of lifestyle-limiting claudication are eligible~* Acute PAO with a need for urgent surgical intervention to restore arterial blood flow in the event of unsuccessful thrombolytic therapy~* Available for follow-up assessments~Exclusion Criteria:~* Contraindication to systemic anticoagulation~* History of endovascular procedure or open vascular surgery on the index limb within the past 30 days~* History of significant acute or chronic kidney disease that would preclude contrast angiography~* Known allergy to contrast agents~* History of heparin induced thrombocytopenia~* Participation in any study of an investigational device, medication, biologic, or other agent within 30 days prior to randomization~* Any thrombolytic therapy within 5 days prior to randomization~* Past participation in any alfimeprase trial~* Pregnant, lactating, or actively menstruating women or women of childbearing potential who are not using adequate contraceptive precautions~* Investigator inability to advance guidewire through index occlusion~* Any other subject feature that in the opinion of the investigator should preclude study participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy